諾輝健康(06606.HK)斥3,000萬美元投資基金
諾輝健康(06606.HK)公布,附屬NHH Ventures Holding Limited於8月20日與基金及NHH Ventures訂立認購協議,將向基金提供3,000萬美元的資本承擔。
該基金主要專注於癌症及其他重大疾病類別領域疾病篩查及早期檢測的分子診斷技術領域的投資。基金期限由2021年6月28日起計八年屆滿,擬於最後截止日或之前籌集承擔總額1億美元。
公司表示,透過投資於基金,將能夠利用基金的基金經理及其他合夥人的專長及資源物色潛在的市場投資目標,相信對投資創新癌症篩查行業的策略佈局形成補充。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.